Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Condition: Covid19 Intervention: Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) Sponsors: Jon Simmons; University of South Alabama Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 24, 2020 Category: Research Source Type: clinical trials
Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial
AbstractObjectivesSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for th...
Source: Trials - June 18, 2020 Category: Research Source Type: clinical trials
Dornase Alpha for the Treatment of COVID-19
Condition: COVID-19 Intervention: Drug: Pulmozyme Sponsors: Acibadem University; The Scientific and Technological Research Council of Turkey Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 16, 2020 Category: Research Source Type: clinical trials
